ECSP19016844A - Combinación de agonistas de fxr - Google Patents

Combinación de agonistas de fxr

Info

Publication number
ECSP19016844A
ECSP19016844A ECSENADI201916844A ECDI201916844A ECSP19016844A EC SP19016844 A ECSP19016844 A EC SP19016844A EC SENADI201916844 A ECSENADI201916844 A EC SENADI201916844A EC DI201916844 A ECDI201916844 A EC DI201916844A EC SP19016844 A ECSP19016844 A EC SP19016844A
Authority
EC
Ecuador
Prior art keywords
fxr agonist
agonist combination
fxr
combination
farnesoid
Prior art date
Application number
ECSENADI201916844A
Other languages
English (en)
Inventor
Bryan Laffitte
Patrick Mueller
Andreas Bauer
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ECSP19016844A publication Critical patent/ECSP19016844A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La invención proporciona composiciones farmacéuticas que comprenden un agonista del receptor farnesoide X (FXR) y otro agente terapéutico, en particular para el tratamiento o la prevención de enfermedades o trastornos hepáticos.
ECSENADI201916844A 2016-09-14 2019-03-11 Combinación de agonistas de fxr ECSP19016844A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662394446P 2016-09-14 2016-09-14

Publications (1)

Publication Number Publication Date
ECSP19016844A true ECSP19016844A (es) 2019-03-29

Family

ID=60043251

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI201916844A ECSP19016844A (es) 2016-09-14 2019-03-11 Combinación de agonistas de fxr

Country Status (23)

Country Link
US (1) US20210290610A1 (es)
EP (1) EP3512558A1 (es)
JP (1) JP6878596B2 (es)
KR (1) KR102218498B1 (es)
CN (1) CN109689105A (es)
AR (1) AR109652A1 (es)
AU (2) AU2017328999B2 (es)
BR (1) BR112019004684A2 (es)
CA (1) CA3036760A1 (es)
CL (1) CL2019000625A1 (es)
CO (1) CO2019002245A2 (es)
CR (1) CR20190125A (es)
EC (1) ECSP19016844A (es)
IL (1) IL264628A (es)
JO (1) JOP20190040A1 (es)
MX (1) MX2019003021A (es)
PE (1) PE20190972A1 (es)
PH (1) PH12019500326A1 (es)
RU (1) RU2019110780A (es)
SG (1) SG11201900651PA (es)
TW (1) TW201811372A (es)
WO (1) WO2018051230A1 (es)
ZA (1) ZA201900528B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11590108B2 (en) * 2017-02-24 2023-02-28 Genfit Pharmaceutical compositions for combination therapy
JP2021525750A (ja) * 2018-05-31 2021-09-27 ノバルティス アーゲー トロピフェクサーとセニクリビロックとを含む組合せ
CA3139750A1 (en) * 2019-07-18 2021-01-21 Jacky Vonderscher Improved treatment using eyp001
KR20220121838A (ko) * 2019-12-20 2022-09-01 노파르티스 아게 인테그린 억제제를 사용한 간 질환의 조합 치료
CN112402430A (zh) * 2020-12-11 2021-02-26 大连医科大学 泽泻醇b-23-醋酸酯在预防和治疗急性肾损伤中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6987121B2 (en) * 2002-04-25 2006-01-17 Smithkline Beecham Corporation Compositions and methods for hepatoprotection and treatment of cholestasis
BRPI0920936A2 (pt) * 2008-11-26 2020-08-11 Pfizer Inc 3-aminociclopentanocarboxamidas como moduladores de receptores de quimiocinas
US8383812B2 (en) 2009-10-13 2013-02-26 Bristol-Myers Squibb Company N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-3-(7-tert-butylpyrazolo[1,5-A][1,3,5]triazin-4-ylamino)-2-oxopyrrolidin-1-yl)cyclohexyl)acetamide, a dual modulator of chemokine receptor activity, crystalline forms and processes
CU24152B1 (es) * 2010-12-20 2016-02-29 Irm Llc 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr
EP3065738B1 (en) * 2013-11-05 2018-02-28 Novartis Ag Compositions and methods for modulating farnesoid x receptors
JP2017510572A (ja) * 2014-03-13 2017-04-13 ソーク インスティチュート フォー バイオロジカル スタディーズ Ｆｘｒアゴニストならびに作製および使用のための方法
RU2723559C2 (ru) * 2014-09-12 2020-06-16 Тобира Терапьютикс, Инк. Комбинированная терапия с применением препарата ценикривирок для лечения фиброза
BR112017011972A2 (pt) * 2014-12-18 2017-12-26 Novartis Ag derivados de azabicicloctano como agonistas de fxr para uso no tratamento de doenças hepáticas e gastrintestinais
WO2017145040A1 (en) * 2016-02-22 2017-08-31 Novartis Ag Methods for using fxr agonists

Also Published As

Publication number Publication date
CR20190125A (es) 2019-06-04
CN109689105A (zh) 2019-04-26
EP3512558A1 (en) 2019-07-24
JOP20190040A1 (ar) 2019-03-10
AU2017328999B2 (en) 2019-12-19
AU2017328999A1 (en) 2019-02-21
ZA201900528B (en) 2021-06-30
RU2019110780A (ru) 2020-10-15
TW201811372A (zh) 2018-04-01
CL2019000625A1 (es) 2019-05-17
PH12019500326A1 (en) 2019-11-11
AU2020201980A1 (en) 2020-04-09
SG11201900651PA (en) 2019-04-29
AR109652A1 (es) 2019-01-09
RU2019110780A3 (es) 2020-11-30
KR20190044666A (ko) 2019-04-30
JP6878596B2 (ja) 2021-05-26
BR112019004684A2 (pt) 2019-05-28
CO2019002245A2 (es) 2019-05-31
JP2019526644A (ja) 2019-09-19
MX2019003021A (es) 2019-09-26
IL264628A (en) 2019-02-28
CA3036760A1 (en) 2018-03-22
PE20190972A1 (es) 2019-07-09
US20210290610A1 (en) 2021-09-23
WO2018051230A1 (en) 2018-03-22
KR102218498B1 (ko) 2021-02-22

Similar Documents

Publication Publication Date Title
PH12019502058A1 (en) Farnesoid x receptor agonists and uses thereof
CO2019002245A2 (es) Combinación de agonistas de fxr
MX2018003388A (es) Agonistas del receptor farnesoide x y usos de los mismos.
CL2018002727A1 (es) Medicina obtenida mediante la combinación de agonista fxr y arb
CL2019000268A1 (es) Composición de cannabis.
CL2018002359A1 (es) Métodos para usar agonistas de fxr
MX382033B (es) Compuestos heterocíclicos para utilizarlos en el tratamiento de trastornos mediados por pi3k-gamma.
MX387720B (es) Composiciones farmacéuticas para el tratamiento de enfermedades mediadas por el regulador de conductancia de transmembrana de fibrosis quística.
MX2021008113A (es) Composiciones farmaceuticas que comprenden un antagonista de il-4r para usarse en el tratamiento del asma.
SA518400356B1 (ar) مثبطات الأرجيناز واستخداماتها العلاجية
BR112018003984A2 (pt) anticorpos
CR20160485A (es) Compuesto de ciclopropanamina y sus usos
CR20190394A (es) Compuestos de inhibidores de autotaxina
MX386547B (es) Combinación de un antagonista con muerte programada 1 (pd-1) y eribulina para el tratamiento de cáncer.
CL2019000914A1 (es) Composiciones de combinaciones que comprenden agonistas de fxr para tratar o prevenir una enfermedad o un trastorno fibrótico o cirrótico.
CL2020002624A1 (es) Formulaciones de inmunoconjugado anti-cd79b estables.
EP3526195A4 (en) SULFOXYALKYL ORGANONITRO AND RELATED COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR USE IN MEDICINE
MX392470B (es) Composición farmacéutica que comprende un péptido wt1 para el tratamiento o prevención de una enfermedad angiogénica.
MX392182B (es) Combinaciones de dosis fija y formulaciones que comprenden ácido 8-hidroxi-2,2,14,14 tetrametilpentadecanodioico (etc1002) y ezetimiba y métodos para tratar o reducir el riesgo de enfermedad cardiovascular.
CL2018003338A1 (es) Formulaciones inyectables fisiológicamente balanceadas de fosnetupitant.
BR112018015367A2 (pt) carreadores oromucosais de nanofibra para tratamento terapêutico
ECSP16086247A (es) (s)-pirlindole y sus sales farmacéuticamente aceptables para uso en medicina
UY36732A (es) Piridin pirazinonas novedosas como inhibidores de bromodominios de la familia bet
ECSP16086232A (es) (r) -pirlindole y sus sales farmacéuticamente aceptables para uso en medicina
CR20170125A (es) Composición farmacéutica sólica que comprende amlodipina y losartán